A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification.
about
Comprehensive analysis of proteins of pH fractionated samples using monolithic LC/MS/MS, intact MW measurement and MALDI-QIT-TOF MSDifferential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry.Proteomics and the analysis of proteomic data: an overview of current protein-profiling technologiesProteomics in cancer vaccine development.Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic modelCharacterization of apolipoprotein and apolipoprotein precursors in pancreatic cancer serum samples via two-dimensional liquid chromatography and mass spectrometry.Prion disease diagnosis by proteomic profiling.Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas.Identification of Critical Elements for Regulation of Inorganic Pyrophosphatase (PPA1) in MCF7 Breast Cancer Cells.Proteomic study of benign and malignant pleural effusion.Breast tumor metastasis: analysis via proteomic profiling.Identifying new PCR targets for pathogenic bacteria using top-down LC/MS protein discovery.Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approachUpregulation of plasma C9 protein in gastric cancer patients.Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage.Methodology and applications of disease biomarker identification in human serum.Structural and Biochemical Characterization of Apicomplexan Inorganic Pyrophosphatases.PPA1 regulates tumor malignant potential and clinical outcome of colon adenocarcinoma through JNK pathways.Pyrophosphatase 1 expression is associated with future recurrence and overall survival in Chinese patients with intrahepatic cholangiocarcinoma.Comparative Proteomics Analysis of Barrett Metaplasia and Esophageal Adenocarcinoma Using Two-dimensional Liquid Mass Mapping
P2860
Q30828985-2603F774-6C9B-4BA0-98D2-78C2EF7BCD90Q30836364-1448BC9E-8BCD-4976-A3D5-76B36F54FC05Q31153300-A26874CE-03CB-44BA-8AEE-1F5317913519Q33215044-7D601FBB-DBFB-40AF-AF50-779062A020E3Q33268322-20AA249A-C232-47B2-9ACB-5DA125E8DA0BQ33282097-3AF2877F-5688-4724-B6C2-9BD32BAA6CD0Q33398738-0664339B-4B20-4E61-A0EB-58751A88011FQ33890039-DA4E6064-D338-46D5-AAD7-A8B97DDCA30AQ35553475-20A864F4-2DF2-491B-943E-E77F18CF1CB0Q35946652-74154F87-8476-4C04-9543-5309A94E59D7Q36146166-B3604B05-20BD-48A7-A840-E6863A77056DQ36537280-6FC9D611-4961-494D-8BC5-EB73F59A9FE8Q37072722-F4231AE8-E92C-4748-A083-71CCCD91F596Q37139908-92306B89-ECCE-4E35-B3AC-D14E6686091FQ37219890-E8AEBFB5-42A1-427B-BC89-3DC65D4F9237Q37574961-6FC51B11-65FD-42BD-88D8-72F4F7C2E9E0Q40998968-0DC9BBEC-5780-4ED4-B5F5-183CEF1D0EB5Q41709327-89358D5E-70F7-44D2-8557-5F27A086DAAEQ55383888-9BF60910-D1B0-4DC7-A2B2-6BCF00BA289AQ58053810-7EEF9EB0-7BF0-40A2-B01A-57157DF3F146
P2860
A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A two-dimensional liquid-phase ...... and biomarker identification.
@ast
A two-dimensional liquid-phase ...... and biomarker identification.
@en
type
label
A two-dimensional liquid-phase ...... and biomarker identification.
@ast
A two-dimensional liquid-phase ...... and biomarker identification.
@en
prefLabel
A two-dimensional liquid-phase ...... and biomarker identification.
@ast
A two-dimensional liquid-phase ...... and biomarker identification.
@en
P2093
P356
P1433
P1476
A two-dimensional liquid-phase ...... and biomarker identification.
@en
P2093
David M Lubman
Fred R Miller
Maureen T Kachman
Nathan S Buchanan
Paweena Kreunin
Rick L Hamler
P304
P356
10.1002/PMIC.200300606
P577
2004-03-01T00:00:00Z